- Jul 08, 2020 Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target
- Jan 09, 2020 Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors
- Sep 16, 2019 Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments
- Dec 13, 2018 Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer
- Mar 14, 2018 Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million
Displaying 111 - 115 of 115